Onconova Therapeutics, Inc. (ONTX) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.35: the stock has moved about 35% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerOnconova Therapeutics, Inc. (ONTX) trades at $20.48. Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Their pipeline includes narazaciclib and rigosertib, targeting solid tumors, hematological malignancies, and non-small cell lung cancer. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for ONTX: ONTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Onconova Therapeutics, Inc. (ONTX) Healthcare & Pipeline Overview
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel cancer therapies, including narazaciclib and rigosertib. These targeted kinase inhibitors are in Phase I and Phase I/IIa clinical trials, positioning Onconova in the competitive oncology therapeutics market.
What Is the Investment Thesis for ONTX?
Onconova Therapeutics presents a high-risk, high-reward investment profile characteristic of clinical-stage biopharmaceutical companies. The primary value drivers are the clinical advancements of narazaciclib and rigosertib. Successful progression through clinical trials and eventual FDA approval could lead to significant revenue generation. Key catalysts include the Phase I data readout for narazaciclib in solid tumors and hematological malignancies, and the Phase I/IIa results for rigosertib in combination with a PD-1 inhibitor for non-small cell lung cancer. However, the company's negative profit margin of -326.2% and reliance on external funding pose significant risks. Investment hinges on positive clinical trial outcomes and the ability to secure additional financing.
Based on FMP financials and quantitative analysis
ONTX Key Highlights
Market capitalization of $0.02 billion reflects the company's early stage and speculative nature.
- Gross margin of 99.9% indicates strong potential profitability upon successful commercialization of its drug candidates.
- P/E ratio of -1.38 reflects the company's current lack of profitability.
- Beta of 1.35 suggests higher volatility compared to the overall market.
- Two clinical-stage programs, narazaciclib and rigosertib, represent the core value drivers for the company.
Who Are ONTX's Competitors?
ONTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CSCI COSCIENS Biopharma Inc. | $2.72 | -0.00% | $8.57M | — |
| DOMH Dominari Holdings Inc. | $2.24 | +6.41% | $50.7M | — |
| ELEV ELEV | $0.36 | -2.12% | $21.6M | — |
| LSB LakeShore Biopharma Co., Ltd | $0.63 | 0.00% | $25.8M | — |
| NVO Novo Nordisk A/S | $37.32 | -0.21% | $166B | 91 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $504.73 | -0.40% | $128B | 97 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $735.20 | +0.05% | $75.7B | 94 5-pillar |
| ARGX argenx SE | $919.21 | -1.79% | $57.2B | 97 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ONTX's Key Strengths?
Proprietary drug candidates in clinical development.
- Experienced management team with expertise in oncology.
- Strategic partnerships with pharmaceutical companies.
- Strong intellectual property portfolio.
What Are ONTX's Weaknesses?
Limited financial resources.
- Dependence on clinical trial outcomes.
- High cash burn rate.
- Lack of commercialized products.
What Are the Key Risks for ONTX?
Negative return on equity (-0.5%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures or delays.
- Regulatory hurdles and rejection of drug candidates.
- Competition from established pharmaceutical companies.
- Dependence on external funding and potential dilution of shareholders.
- Patent expirations and loss of exclusivity.
What Are ONTX's Competitive Advantages?
- Proprietary drug candidates in clinical development.
- Intellectual property protection through patents.
- Established partnerships with pharmaceutical companies.
- Expertise in oncology drug development.
What Does ONTX Do?
Onconova Therapeutics, Inc., established in 1998 and headquartered in Newtown, Pennsylvania, is a biopharmaceutical company dedicated to discovering and developing innovative therapies for cancer treatment. The company focuses on addressing unmet medical needs in oncology through its clinical-stage programs. Onconova's pipeline features two primary clinical-stage assets: narazaciclib (ON 123300) and rigosertib. Narazaciclib is a multi-targeted kinase inhibitor currently in Phase I clinical trials for solid tumors and hematological malignancies, both as a single agent and in combination with other anti-cancer therapies. Rigosertib, available in oral form, is being evaluated in a Phase I/IIa study in combination with a PD-1 inhibitor for the treatment of progressive K-Ras mutated non-small cell lung cancer. Additionally, Onconova is exploring rigosertib monotherapy in a Phase Ib/II ISS study for advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. The company also has a preclinical program evaluating IV/oral rigosertib for the treatment of COVID-19. Onconova has established strategic partnerships to support the development and commercialization of its therapies, including license agreements with SymBio Pharmaceuticals Limited, Pint International SA, and HanX Biopharmaceuticals, Inc.
What Products and Services Does ONTX Offer?
- Develop novel products to treat cancer.
- Focus on clinical-stage programs.
- Develop multi-targeted kinase inhibitors.
- Conduct Phase I studies for solid tumors and hematological malignancies.
- Develop oral rigosertib in combination with PD-1 inhibitors for non-small cell lung cancer.
- Develop rigosertib monotherapy for advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa.
- Conduct preclinical programs for IV/oral rigosertib for COVID-19.
How Does ONTX Make Money?
- Discovering and developing novel cancer therapies.
- Out-licensing or partnering to commercialize developed therapies.
- Generating revenue through milestone payments and royalties from partnerships.
- Securing funding through equity offerings and strategic collaborations.
What Industry Does ONTX Operate In?
Onconova operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high failure rates. The oncology therapeutics market is experiencing substantial growth, driven by an aging population and advancements in personalized medicine. Onconova's focus on targeted kinase inhibitors and combination therapies aligns with current market trends. Competitors like ATON, CSCI, DOMH, ELEV, and LSB are also vying for market share in the oncology space, emphasizing the need for Onconova to demonstrate clinical efficacy and secure regulatory approvals.
Who Are ONTX's Key Customers?
- Patients with cancer.
- Hospitals and oncology clinics.
- Pharmaceutical companies through licensing agreements.
- Research institutions through collaborations.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 41 snapshots
| 2026-08-23 | 44 |
| 2026-08-31 | 44 |
| 2026-09-08 | 44 |
| 2026-09-16 | 44 |
| 2026-09-24 | 44 |
| 2026-10-04 | 44 |
What changed?
The score has stayed at 44.
Over the same 30 days the stock moved +60.1%.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Forward Outlook
Wall Street analysts project Onconova Therapeutics, Inc. revenue of about $300K for fiscal 2026, with EPS near $-0.81.
Key Financial Metrics
Return on equity for Onconova Therapeutics, Inc. stands at -0.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.43 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -9.8%, the inverse of the P/E and a quick read on earnings relative to price.
ONTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary drug candidates in clinical development.
- Experienced management team with expertise in oncology.
- Strategic partnerships with pharmaceutical companies.
- Strong intellectual property portfolio.
Bear Case
- Limited financial resources.
- Dependence on clinical trial outcomes.
- High cash burn rate.
- Lack of commercialized products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ONTX Latest News
No recent news available for ONTX.
ONTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ONTX.
Price Targets
Wall Street price target analysis for ONTX.
ONTX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ONTX; grades run from A+ (80-100) to F (below 30).
Leadership: Steven M. Fruchtman
CEO
Steven M. Fruchtman serves as the CEO of Onconova Therapeutics, bringing extensive experience in hematology and oncology. Prior to joining Onconova, he held leadership positions at numerous pharmaceutical companies, guiding clinical development programs and commercialization strategies. His background includes significant contributions to the development and approval of several cancer therapies. Fruchtman's expertise spans clinical research, regulatory affairs, and business development, making him well-suited to lead Onconova through its clinical development milestones.
Track Record: Under Steven M. Fruchtman's leadership, Onconova has focused on advancing its clinical-stage programs, particularly narazaciclib and rigosertib. He has overseen the initiation and progression of clinical trials, secured strategic partnerships, and managed the company's financial resources. Fruchtman's strategic decisions have been instrumental in positioning Onconova for potential success in the competitive oncology market.
Onconova Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for ONTX?
Onconova faces several key risks inherent to clinical-stage biopharmaceutical companies. Clinical trial failures represent a significant risk, as negative results could halt the development of drug candidates and significantly impact the company's value. Regulatory hurdles and potential rejection of drug candidates by the FDA also pose a threat.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.